CR20210616A - Formas de sales cristalinas de un inhibidor de cinasas - Google Patents

Formas de sales cristalinas de un inhibidor de cinasas

Info

Publication number
CR20210616A
CR20210616A CR20210616A CR20210616A CR20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
relates
compound
Prior art date
Application number
CR20210616A
Other languages
English (en)
Spanish (es)
Inventor
Courtney S Johnson
Peter Wong
Frenel Demorin
Sagar Shakya
Melanie Janelle Bevill
Stephan D Parent
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20210616A publication Critical patent/CR20210616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CR20210616A 2019-06-03 2019-12-12 Formas de sales cristalinas de un inhibidor de cinasas CR20210616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CR20210616A true CR20210616A (es) 2022-03-22

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210616A CR20210616A (es) 2019-06-03 2019-12-12 Formas de sales cristalinas de un inhibidor de cinasas

Country Status (22)

Country Link
US (1) US20230052703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579281B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826380B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939503B (cg-RX-API-DMAC7.html)
AU (1) AU2019449809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139148A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003205A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017343A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210616A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000236A (cg-RX-API-DMAC7.html)
ES (1) ES3008963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247655B (cg-RX-API-DMAC7.html)
IL (1) IL288484A (cg-RX-API-DMAC7.html)
MA (1) MA56001A (cg-RX-API-DMAC7.html)
MX (1) MX2021014773A (cg-RX-API-DMAC7.html)
PE (1) PE20220962A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111978VA (cg-RX-API-DMAC7.html)
WO (1) WO2020247019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108034B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
GEAP202415849A (en) 2024-03-11
CO2021017343A2 (es) 2022-01-17
GEP20247655B (en) 2024-08-26
BR112021024300A2 (pt) 2022-01-11
CN113939503B (zh) 2024-05-07
SG11202111978VA (en) 2021-11-29
WO2020247019A1 (en) 2020-12-10
KR20220016117A (ko) 2022-02-08
CA3139148A1 (en) 2020-12-10
MX2021014773A (es) 2022-01-18
MA56001A (fr) 2022-04-06
EP3976587B1 (en) 2024-12-04
CL2021003205A1 (es) 2022-09-30
EP3976587A1 (en) 2022-04-06
JP2022535072A (ja) 2022-08-04
PH12021553020A1 (en) 2023-08-23
KR102826380B1 (ko) 2025-06-26
ES3008963T3 (en) 2025-03-25
DOP2021000236A (es) 2022-04-18
US20230052703A1 (en) 2023-02-16
PE20220962A1 (es) 2022-06-10
CN113939503A (zh) 2022-01-14
AU2019449809A1 (en) 2021-12-16
ZA202108034B (en) 2025-02-26
AU2019449809B2 (en) 2026-02-05
IL288484A (en) 2022-01-01
EP3976587C0 (en) 2024-12-04
JP7579281B2 (ja) 2024-11-07

Similar Documents

Publication Publication Date Title
CR20210375A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
EA201792214A1 (ru) Соединения замещенного хиназолина
MX2023007192A (es) Inhibidores de prmt5.
PH12020552187A1 (en) Pcsk9 antagonist compounds
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021015262A (es) Inhibidores de prmt5.
EA201690752A1 (ru) Ингибиторы g12c kras
PH12021552482A1 (en) Compounds targeting prmt5
EA201991884A3 (ru) Ингибиторы g12c kras
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
PH12021552513A1 (en) Pyrrole compounds
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
PH12019501566B1 (en) Amide compounds and use thereof
CR20230223A (es) Composiciones farmacéuticas de un inhibidor de cinasa
MX2024009648A (es) Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida.
EA202191653A1 (ru) Кристаллические формы и солевые формы ингибитора киназы
EA202192382A1 (ru) Соединения, нацеленные на prmt5
ZA202300107B (en) Pharmaceutically acceptable salts of sepiapterin